OrbiMed
VC Fund
New York, United States
OrbiMed is a VC fund in New York focused on Biotechnology and Health Care. OrbiMed executes multiple investment strategies, including private equity for startups, public equity for traded entities, and private credit for commercial-stage companies. It offers structured debt and royalty monetization as non-dilutive financing solutions for owners of intellectual property and medical diagnostics. The firm manages a global portfolio that supports the development of new therapies, medical devices, and healthcare information technology systems.
- Total investments:
- 768
- Last investment:
- Lead investor:
- 35%
- Fund size:
- $192M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries OrbiMed invests in
Stages OrbiMed invests in
Countries OrbiMed invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 25 contacts → | |||
Round size
- Series A
- $9M–$116M
- Series B
- $23M–$148M
- Series C
- $19M–$160M
Investment Focus
Industry
- Biotechnology 342 (45%)
- Health Care 271 (35%)
- Pharmaceutical 136 (18%)
- Medical 134 (17%)
- Therapeutics 129 (17%)
Stage
- Series B 152 (20%)
- Series A 129 (17%)
- Series C 110 (14%)
- Post-IPO Equity 72 (9%)
- Venture - Series Unknown 43 (6%)
Country
- United States 285 (37%)
- China 58 (8%)
- Israel 23 (3%)
- India 15 (2%)
- Canada 13 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Dina Chaya
Partner
|
Partner | Total investments: 7 | Find email | |
Kevin Koch
Venture Partner
|
Venture Partner | Total investments: 3 | Find email | |
Rishi Gupta
Private Equity Partner
|
Private Equity Partner | Total investments: 12 | Find email | |
Sunny Sharma
Senior Managing Director
|
Senior Managing Director | Total investments: 11 | Find email | |
Tadd S. Wessel
Managing Director
|
Managing Director | Total investments: 10 | Find email | |
| See all 25 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Pyxis Oncology is a developer of antibody therapeutics intended to promote the body's immune response to cancer. The company has engaged in deep analyses of tumor antigen-specific tumor-infiltrating lymphocytes (TILs) within hot tumors and of tumor cell signaling pathways within cold tumors, providing laboratories with development of novelantibody-based immunotherapies.It was founded in 2019 and is based in Boston, Massachusetts. | $110M / Post-IPO Equity / Sep 29, 2026 | ||
| Altis Labs is the computational imaging company advancing precision medicine. We believe that medical imaging is the richest source of untapped information. Life sciences companies use our software platform, Nota, to accelerate all stages of clinical development. Trained on over 140 million longitudinal real-world images with associated clinicalinformation, our deep learning models predict clinically meaningful outcomes to quantify treatment effect more accurately. | $25M / Series A / Sep 17, 2026 | ||
|
Connexus Therapeutics
|
Connexus Therapeutics is a private, venture-backed biotechnology company specializing in the discovery and development of next-generation small-molecule drugs for oncology treatment . | $5M / Series A / Sep 17, 2026 | |
| Intellia Therapeutics is a genome editing company that develops curative gene-editing treatments. It can positively transform the lives of people living with severe and life-threatening diseases. IIntellia holds exclusive access to one of the most comprehensive intellectual property platforms available for the therapeutic use of CRISPR-Cas9. Thecompany is advancing a broad pipeline toward clinical development, including ex Vivo, and in vivo approaches. Intellia Therapeutics was formed in 2014 and is headquartered in Cambridge, Massachusetts. | $75M / Post-IPO Debt / Sep 04, 2026 | ||
| Leal Therapeutics develops novel therapeutics for patients. | $30M / Series A / Aug 17, 2026 | ||
| TytoCare is a mobile-health platform and device, allowing anyone to perform self physical examination and remote diagnosis.Tyto Care has three telehealth products: the TytoHome for consumers, TytoPro for professionals, and TytoClinic for remote point-of-care locations. All solutions are designed to replicate a facetious clinician visit andinclude a modular examination tool for examining the heart, lungs, skin, throat, ears, and body temperature; a complete telehealth platform for sharing exam data, conducting live video exams, and scheduling visits; a cloud-based data repository with analytics; and built-in guidance technology and machine learning algorithms to ensure accuracy and ease of use. TytoCare was founded by Dedi Gilad, Ofer Tzadik in 2012 with a vision to put health in the hands of the consumer. | $25M / Venture - Series Unknown / Jul 15, 2026 | ||
| Iswarya Fertility Center provides IVF, IUI, egg donation, azoospermia, ovulation induction, and miscarriage treatment solutions. | $37M / Private Equity / Jul 09, 2026 | ||
| We are a precision oncology company pioneering the development of cancer therapies guided by our proprietary functional genomics. | $67.4M / Series D / Jul 07, 2026 | ||
| Lycia Therapeutics is a biotechnology company that focuses on developing technology that utilizes lysosome-targeting chimeras. The company was founded by Carolyn R. Bertozzi in 2019 and is based in San Diego, California, USA. | $75M / Series D / Jun 25, 2026 | ||
| Asian Institute of Medical Sciences is a 425 bedded super specialty hospital in Delhi NCR, India which is dedicated to provide accessible, affordable and best available healthcare services in India. Accredited by NABH and NABL, Asian Hospital Faridabad provides preventive, diagnostic, therapeutic, rehabilitative, palliative and supportive servicesall under one roof and is designed to meet patient care and research requirements of the new millennium.Asian Institute of Medical Sciences offers comprehensive multi-specialty tertiary care facilities through its 14 centres of excellence.- ASIAN CANCER CENTRE - ASIAN CENTRE FOR BONE MARROW TRANSPLANT - ASIAN HEART CENTRE - ASIAN CENTRE FOR ADVANCED SURGERY- ASIAN CENTRE FOR NEUROLOGY AND NEUROSURGERY - ASIAN CENTRE FOR UROLOGY AND KIDNEY TRANSPLANT - ASIAN CENTRE FOR RENAL DISEASES - ASIAN CENTRE FOR BONE AND JOINTS - ASIAN CENTRE FOR ADVANCED IMAGING - ASIAN CENTRE FOR GASTROENTEROLOGY - ASIAN CENTRE FOR MOTHER AND CHILD- ASIAN CENTRE FOR BARIATRIC & METABOLIC SURGERY - ASIAN CENTRE FOR AESTHETIC SURGERY & MEDICINE - ASIAN IVF CENTRE | $44M / Debt Financing / Jun 19, 2026 | ||
| See all 768 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does OrbiMed invest in?
OrbiMed invests primarily in Biotechnology, Health Care and Pharmaceutical startups, most often at Series B and Series A stage. Most of the 768 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does OrbiMed invest in?
OrbiMed typically joins rounds of $9M–$116M at Series A, $23M–$148M at Series B and $19M–$160M at Series C. These are whole funding-round sizes, not OrbiMed's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds OrbiMed took part in.
How do I contact OrbiMed?
Public channels for OrbiMed include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at OrbiMed?
The team at OrbiMed includes Dina Chaya (Partner), Kevin Koch (Venture Partner) and Rishi Gupta (Private Equity Partner), among 25 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
